Wedbush Remains Neutral on BioMarin Pharma (BMRN) - PT to $104
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Wedbush maintained a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and cut the price target to $104.00 (from $108.00), as the PDUFA date for Brineura for CLN2 disease was delayed to April 27, 2017.
Analyst Liana Moussatos commented, "We consider the PDUFA extension and plans for an advisory committee for Brineura treatment of CLN2 disease as a minor negative. Due to the high unmet need, we believe Brineura is likely to receive first-pass approval."
Shares of BioMarin Pharmaceutical Inc. closed at $95.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- E*TRADE (ETFC) PT Raised to $33 at Nomura Post Q3
- BMO Capital Raises Price Target on Halliburton (HAL) Following 3Q Report
- PayPal (PYPL): Improving Visibility, Raising PT - Wedbush
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesLiana Moussatos, PDUFA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!